The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

Anti-tetraspanin monoclonal antibodies, tetraspanin-derived recombinant soluble extracellular loops and RNAi knockdown strategies have all shown potential for effective modulation of tetraspanin ...

Designs Serum exosomes from patients with GC (n=37) and healthy donors (n=20) were characterised using RNA sequencing, and potential biomarkers for GC were validated ... Furthermore, molecular ...